Govt focussing on production of high-value pharmaceuticals: Health Minister

The financial year of 2022-2023 being the first year of production for the PLI Scheme, DoP has earmarked Rs 690 crore as the budget outlay

Mansukh L Mandaviya
Union Health Minister Mansukh L Mandaviya
Press Trust of India New Delhi
3 min read Last Updated : Feb 21 2023 | 7:14 PM IST

The government is taking steps to produce "high value pharmaceuticals" in the country to reduce import dependency for such critical articles, Union Minister Mansukh Mandaviya said on Tuesday.

Manufacturing of components of high-end medical devices in the country will be another big step in moving towards self reliance, the Union Minister for Chemicals and Fertilisers noted.

"Working on the vision of reducing import dependency through indigenous production, the government is focussing on production of high value pharmaceuticals and high-end medical devices," he said.

Mandaviya said the Department of Pharmaceuticals (DoP) has released the first tranche of incentives under the Product Linked Incentive (PLI) scheme of pharmaceuticals amounting to Rs 166 crore to four selected applicants.

Under the Atmanirbharta initiative of the government, DoP launched the PLI scheme for pharmaceuticals in 2021.

The financial outlay under this PLI scheme is Rs 15,000 crore over a period of six years.

So far, 55 applicants have been selected under the scheme, including 20 Micro, Small & Medium Enterprises (MSMEs).

The financial year of 2022-2023 being the first year of production for the PLI Scheme, DoP has earmarked Rs 690 crore as the budget outlay.

Against the expected investment of Rs 17,425 crore in the pharmaceutical sector over the scheme period, the scheme has garnered an investment of Rs 16,199 crore by these 55 applicants in the first year of implementation itself, the ministry said.

Against the expected employment of 1 lakh over six years scheme period, 23,000 people have been given employment, so far, it added.

The DoP has received an incentive claim of about Rs 544 crore from 15 applicants, it said.

Based on the evaluation, Rs 221 crore of claims of incentives from four applicants -- Dr Reddy's Laboratories, Biocon Ltd, Strides Pharma Science Ltd, Premier Medical Corporation Pvt Ltd -- were found to be eligible and 75 per cent of this amount (Rs 165.74 crore) have been released, it added.

Remaining incentives are under examination, the statement said.

Under the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crore, the objective is to boost domestic production of 41 select critical bulk drugs in the country.

So far, 51 projects have been selected for the 34 notified bulk drugs, it added.

Moreover, a total of 21 applicants have been selected under the PLI scheme for medical devices with a financial outlay of Rs 3,420 crore, it said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Pharamaceutical IndustriesMansukh Lal MandaviyaHealth Ministry

First Published: Feb 21 2023 | 7:14 PM IST

Next Story